Norio Yamamoto

Kanazawa University — Japan

Medicine · Health Sciences

50h-index9.2kcitations516works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(166), Cancer Research and Treatments(94), Bone Tumor Diagnosis and Treatments(91), Virus-based gene therapy research(57), Nanoplatforms for cancer theranostics(40)

Publications516 total

Human fibrosarcoma cells selected for ultra-high doxorubicin resistance, acquire trabectedin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expression
Frontiers in Oncology·2025Open Access
Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal Fibroblasts
Anticancer Research·2025Open Access
Very Rapid Eradication of a Large Squamous-Cell Carcinoma of the Head and Neck Treated With First-line Combination Chemotherapy, a Low-methionine Diet, and Oral Recombinant Methioninase
Anticancer Research·2025
Triple Combination of Recombinant Methioninase and the Anti-parasitic Drugs Ivermectin, and Chloroquine Selectively Eradicates Pancreatic Cancer Cells While Sparing Normal Fibroblasts
Anticancer Research·2025· 1 cited
Eradication of Extensive Lymph‐Node, Bone and Pleural Metastases of a Breast‐Cancer Patient Treated With Radiation, Immunotherapy and Oral Recombinant Methioninase
Cancer Diagnosis & Prognosis·2025· 1 citedOpen Access
LBA74 Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1
Annals of Oncology·2025· 1 citedOpen Access
Limited predictive value of pretreatment P-glycoprotein immunostaining for chemotherapy efficacy and survival in long-follow-up osteosarcoma patients
Medicine·2025Open Access
491P Zongertinib in HER2-altered gastrointestinal cancers: Preclinical activity and clinical findings from a phase Ia study
Annals of Oncology·2025· 1 citedOpen Access
A perspective on patient-derived orthotopic xenograft (PDOX) mouse models for identification of novel and individualized treatment for sarcoma
International Journal of Clinical Oncology·2025
Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts
Anticancer Research·2025· 1 citedOpen Access
HT1080 Human Fibrosarcoma Cells Selected for Super-eribulin Resistance <i>In Vitro</i> Become More Malignant and Are Arrested Synergistically by Methionine Restriction in Combination With Eribulin in Nude Mice
In Vivo·2025· 2 citedOpen Access
Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting<i>Salmonella typhimurium</i>A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude Mice
In Vivo·2025Open Access
HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine Restriction
In Vivo·2025· 2 citedOpen Access
Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin
Anticancer Research·2025· 1 citedOpen Access
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse Models
In Vivo·2024Open Access
Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells
Anticancer Research·2024· 2 citedOpen Access
639P A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-stage small cell lung cancer (WJOG13520L, REBORN trial)
Annals of Oncology·2024
Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal Fibroblasts
Anticancer Research·2024· 5 citedOpen Access
Enhancing Precision and Esthetics: Endoscopy-Assisted Total Maxillectomy for Locally Invasive Maxillary Ameloblastoma Using Contralateral Transmaxillary Approach Without Subciliary Incision
Cureus·2024Open Access
Accurate and Safe Tumor Targeting of Orally-administered<i>Salmonella typhimurium</i>A1-R Leads to Regression of an Aggressive Fibrosarcoma in Nude Mice
In Vivo·2024Open Access
page 1 of 26Next →

Frequent Co-authors

Hiroyuki Tsuchiya(36), Katsuhiro Hayashi(24), Robert M. Hoffman(16), Katsuro Tomita(15), Shinji Miwa(13), Akihiko Takeuchi(12), Kentaro Igarashi(11), Kensuke Yamauchi(10), Michael Bouvet(8), Toshiharu Shirai(8), Hideji Nishida(8), Ping Jiang(6), Hiroaki Kimura(6), Meng Yang(5), Hiroaki Kimura(5), Kei Kawaguchi(5), Arun S. Singh(5), Mingxu Xu(4), Koji Watanabe(4), Ming Zhao(4)